We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.675 | 4.36 | 4.99 | - | 38,838 | 08:00:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.53 | 9.41M |
Date | Subject | Author | Discuss |
---|---|---|---|
02/4/2020 16:11 | Waterloo It had crossed my mind too about taste or smell of the SNG001 as a differentiator to the placebo. For example, if it had a strong metallic taste, I'm sure the placebo wouldn't be 'flavoured' to match the drug and I'm also sure if a strong taste, patients would also remark on it to the staff on the ward. There's possibility of small temporary side effects too, such as a very dry mouth after use, which might not be present with a placebo, as an example, etcetc, so for me, after several days, it will become fairly clear to those administering the drug or those staff just 'around' the patient because patients and staff do talk, it's human nature. | jev1 | |
02/4/2020 16:09 | >>waterloo And I agree with your criteria for stopping a trial and that they are extremely unlikely to apply here. | nobbygnome | |
02/4/2020 15:55 | It's a protein and they tend to be odourless because they are not volatile in any way. Plus I assume it will be in the same buffer as the placebo if that has an odour. You can sometime tell from the viscosity of the liquid but in this case you won't be able to see it. | nobbygnome | |
02/4/2020 15:53 | unless it has as strong taste or smell? But agree re blinded trials. Only get stopped (and not such a short time frame trial) if it either kills people (which they wouldn't pick up given the nature of COVID) or clear benefit (which would have to be stark) | waterloo01 | |
02/4/2020 15:50 | Perfectly reasonable comment! There are going to be I think up to 11 sites. So around 10 patients per site in a new disease where no-one knows what to expect. As previously discussed no-one will know how many placebo patients you have and vice versa and due to nature of the delivery device no-one can see the drug so no chance to guess from the appearance. The reality is that human nature will mean doctors try to guess who gets what from their observations. However, they can most definitely be wrong as I described yesterday. I was involved in the trial of a drug for lupus which spectacularly failed where 2 medics told me from their limited experience of having patients in the trial that it had definitely worked! I will make one concession. If the response really was dramatic so that say after a couple of doses the patients massively improved in about 80% of cases that might become obvious quite quickly. However, I stress I don't expect that to happen but you never know.... | nobbygnome | |
02/4/2020 15:36 | Nobby, yes grateful for your knowledge of the sector. Very helpful. | rafboy | |
02/4/2020 15:34 | Yeah Nobby, info also gratefully received from another thicko ;-) | finster007 | |
02/4/2020 15:31 | Torreskid that's interesting. | hazl | |
02/4/2020 15:22 | Second that cheers Nobby for making the time to enlighten us thickos. | talk2dubya | |
02/4/2020 15:22 | Nobby, multicentre as well, so each unit will have limited 'exposure' to trial patients so difficult to anticipate if placebo or active drug , eg Southampton probably enrol the most then other units will enrol less depending on when they get onboard I was involved in the good old 'clot busting' trials in heart attacks, and after a while even though blinded, you could tell who was receiving active drug (but this was only after our unit had experience with many patients | torreskid | |
02/4/2020 15:16 | However of course we are lucky to have someone as informed as yourself to provide facts about how this works. | hazl | |
02/4/2020 15:14 | People can have something to offer even if they are not trained bio-scientists. Let's just leave it at that. Most people that are interested in this share have enough knowledge to have an informed opinion. | hazl | |
02/4/2020 15:12 | Here are the salient points 1. It is a double blind trial so no-one knows who gets drug and who gets placebo 2. Some of the patients who get placebo will get better 3. No drug works in every single patient so some who get SNG001 will get worse and go into the ICU 4. The trial is randomised which means that if you treat 10 patients in Southmampton, it is possible that all 10 will get placebo. Alternatively all 10 could get drug or any combination in between 5. No-one will know the results until they are unblinded. There isn't even a comparator group from a previous trial to determine the normal response rate because this is a new disease I am sure I will think of some more reasons... | nobbygnome | |
02/4/2020 15:09 | anybody seen somutroll he might be at that garbage 4d pharma loooo | manc10 | |
02/4/2020 15:08 | If you really want me to explain again why what he said was nonsense I am happy to do that. | nobbygnome | |
02/4/2020 15:07 | >> hazl If someone posts nonsense on either side, I am going to ban them. He posted similar rubbish yesterday and others and I told him where he was mistaken. He just carried on today presumably because he is a trader who is desperate to get the price up. Yes I want the price to go up but when it is good and ready. | nobbygnome | |
02/4/2020 15:03 | Haha just bought £500 and it recorded it as a sell,! WTF | makendon | |
02/4/2020 15:03 | What even the DOCTORS in the team at Southampton?!! | hazl | |
02/4/2020 15:02 | Clearly some have sold their trading shares and dont mind the share price drifting to where they can pick up more. Nothing wrong with that but this has become a very engineered thread. | hazl | |
02/4/2020 15:00 | Hazl - We have to keep it objective, that includes pro or con. I don’t mind links with facts or info but drawing conclusions from a Twitter profile is laughable. | finster007 | |
02/4/2020 15:00 | I am disappointed in you for treating all users of twitter with the same brush. | hazl | |
02/4/2020 14:59 | Ah great find Bloomberg2! | hazl |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions